Big win for brand-name pharma companies in PTAB final decision
In a PTAB decision that brand-name pharmaceutical companies will celebrate, generic drug company Amneal has failed in its attempt to have three patents owned by Galderma cancelled – the first final written decision to involve an Orange Book-listed patent
Generic drug company Amneal had challenged the claims of three patents owned by Galderma that covered blockbuster drug Oracea on grounds of obviousness. The Patent Trial and Appeal Board (PTAB) this week in three final written decisions said Amneal had...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.